Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial

Jin Li(Fudan University Shanghai Cancer Center), Shukui Qin(81th Hospital of PLA), Rui‐Hua Xu(Sun Yat-sen University), Thomas Yau(University of Hong Kong), Brigette Ma(Chinese University of Hong Kong), Hongming Pan(Sir Run Run Shaw Hospital), Jianming Xu(307th Hospital of Chinese People’s Liberation Army), Yuxian Bai(Third Affiliated Hospital of Harbin Medical University), Yihebali Chi(Chinese Academy of Medical Sciences & Peking Union Medical College), Liwei Wang(Shanghai First People's Hospital), Kun‐Huei Yeh(National Taiwan University Hospital), Feng Bi(Sichuan University), Ying Cheng(Jilin Province Tumor Hospital), Anh T. Le(Cho Ray Hospital), Jen-Kou Lin(National Yang Ming Chiao Tung University), Tianshu Liu(Fudan University), Dong Ma(Guangdong General Hospital), Christian Kappeler(Bayer (Germany)), J. Kalmus(Bayer (Germany)), Tae Won Kim(University of Ulsan)
The Lancet Oncology
May 13, 2015
10.1016/s1470-2045(15)70156-7
Cited by 811

Abstract

Related Papers

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al.|European Journal of Cancer|2008|29.3k
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann‐Lii Cheng, Yoon‐Koo Kang, Zhendong Chen et al.|The Lancet Oncology|2008|5.8k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
George D. Demetri, Peter Reichardt, Yoon‐Koo Kang et al.|The Lancet|2012|1.4k
Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
Scott M. Wilhelm, Jacques Dumas, Lila Adnane et al.|International Journal of Cancer|2010|1.3k
A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
K. Mross, Annette Frost, Simone Steinbild et al.|Clinical Cancer Research|2012|332